Metformin at the convergence of aging and longevity.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and clinical literature without original data or systematic review methodology.
PubMed 42579881 · doi:10.18632/aging.206407
What was done
This was a narrative review synthesizing cellular, molecular, and organismal evidence on metformin's potential geroprotective properties, its mechanisms of action (such as AMPK activation, mTOR inhibition, autophagy, and microbiome modulation), and proposed clinical trials like the Targeting Ageing with Metformin (TAME) study.
What was found
The abstract provides no quantitative data or effect sizes. It qualitatively describes metformin's downstream molecular pathways, its capacity to increase short-chain fatty acid-producing gut bacteria, and its potential role in targeting aging hallmarks and age-associated diseases.
Why it matters
It provides a broad overview of how a widely used, low-cost diabetes drug intersects with modern hallmarks of aging, framing the rationale for clinical trials aimed at targeting aging biology directly.
Limits
The paper is a narrative review presenting no new empirical data or systematic search methodology. Quantitative clinical efficacy for lifespan extension or healthspan improvement in non-diabetic human populations is not reported in the abstract.
Cited by
- supports Metformin stimulates mitochondrial biogenesis.